Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus TESTODERM TTS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus TESTODERM TTS.
HALOTESTIN vs TESTODERM TTS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone is an androgen receptor agonist. It binds to and activates androgen receptors, leading to changes in gene expression that promote the development and maintenance of male secondary sexual characteristics, anabolic effects, and spermatogenesis.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
Apply 4 mg (one 4 mg/24 hr system) or 6 mg (one 6 mg/24 hr system) transdermally once daily, applied to clean, dry, intact skin on the back, abdomen, thighs, or upper arms. Rotate application sites with an interval of at least 7 days.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
The terminal elimination half-life of testosterone administered transdermally is approximately 1.5–2 hours. This short half-life requires daily application of the patch to maintain therapeutic levels.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Testosterone is excreted primarily in the urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category C
Category C
Androgen
Androgen